

In the Claims

Listing of the Claims

This listing of claims will replace all prior versions, and listings, of the claims in the application.

1. (Original) A pharmaceutical composition comprising (i) a first specific binding agent selected from an antibody or a large binding fragment of an antibody which specifically binds a target toxin, and (ii) a second specific binding agent which comprises a small binding fragment of an antibody which binds said toxin.
2. (Currently Amended) ~~A~~ The composition ~~according to~~ of claim 1 wherein the first specific binding agent comprises a large binding fragment of an antibody.
3. (Currently Amended) ~~A~~ The composition ~~according to~~ of claim 2 wherein the large binding fragment of an antibody is ~~a~~ an F(ab')<sub>2</sub> or F(ab)<sub>2</sub> fragment.
4. (Currently Amended) ~~A~~ The composition ~~according to~~ of claim 1 wherein the first specific binding agent is an antibody which is IgG or IgT.
5. (Currently Amended) ~~A~~ The composition ~~according to~~ of claim 4 wherein the antibody is humanised.
6. (Currently Amended) ~~A~~ The composition ~~according to any one of the preceding claims of claim 1~~ wherein the second specific binding agent comprises an Fab, Fab', a single chain (sc) antibody or an FV, VH or VK fragment.
7. (Currently Amended) ~~A~~ The composition ~~according to~~ of claim 6 wherein the second specific binding agent comprises an Fab or Fab' fragment.

8. (Currently Amended) A The composition ~~according to any one of the preceding claims of claim 1~~ wherein the first and/or second binding agents are derived from polyclonal antibodies.
9. (Currently Amended) A The composition ~~according to any one of claims 1 to 7 of claim 1~~ wherein the first and/or second binding agents are derived from monoclonal antibodies.
10. (Currently Amended) A The composition ~~according to any one of the preceding claims of claim 1~~ wherein at least one of the first or second specific binding agents includes a section corresponding to part of the Fc region of an antibody.
11. (Currently Amended) A The composition ~~according to any one of the preceding claims of claim 1~~ wherein the toxin is a Botulinum toxin.
12. (Currently Amended) A The composition ~~according to~~ of claim 11 wherein the first and second specific binding agents bind at least one of type A, B, C, D, E, F or G botulinum toxin.
13. (Currently Amended) A The composition ~~according to~~ of claim 12 wherein the composition comprises sets of first and second specific binding agents each set of specific binding agents binding a different one of botulinum toxins A, B, C, D, E, F or G.
14. (Currently Amended) A The composition ~~according to any one of the preceding claims of claim 1~~ wherein the w/w ratio of the first specific binding agent to the second specific binding agent is in the range of from 90:10 to 10:90.
15. (Currently Amended) A The composition ~~according to~~ of claim 14 wherein the w/w ratio of the first specific binding agent to the second specific binding agent is in the range of from 70:30 to 30:70.

16. (Currently Amended) A The composition ~~according to~~ of claim 15 wherein the w/w ratio of the first specific binding agent to the second specific binding agent is in the range of from 60:40 to 40:60.

17. (Currently Amended) A The composition ~~according to any one of the preceding claims~~ of claim 1 which further comprises a pharmaceutically acceptable carrier or excipient.

18. (Currently Amended) A The composition ~~according to any one of the preceding claims~~ of claim 1 which is suitable for oral, parenteral, or intranasal administration, or for administration by inhalation or insufflation.

19. (Currently Amended) A method for treating the adverse effects of a toxin on a mammal comprising administering to a mammal in thereof a composition comprising combination of (i) a first specific binding agent selected from an antibody or a large binding fragment of an antibody which specifically binds a target toxin, and (ii) a second specific binding agent which comprises a small binding fragment of an antibody which binds said toxin, ~~for use in the treatment of the effects of the toxin.~~

20. (Cancelled)

21. (Currently Amended) A method of preventing the effects of a toxin on a mammal ~~such as a human~~, said method comprising administering to a mammal in need thereof, a composition ~~according to any one of claims 1 to 18~~ comprising (i) a first specific binding agent selected from an antibody or a large binding fragment of an antibody which specifically binds a target toxin, and (ii) a second specific binding agent which comprises a small binding fragment of an antibody which binds said toxin.

22. (Cancelled)